205 related articles for article (PubMed ID: 31140295)
21. PDE-5 inhibitors in selected herbal supplements from the Ghanaian market for better erectile function as tested by a bioassay.
Akuamoa F; Hoogenboom RLAP; Hamers A; Rietjens IMCM; Bovee TFH
Toxicol In Vitro; 2021 Jun; 73():105130. PubMed ID: 33662516
[TBL] [Abstract][Full Text] [Related]
22. Discovery of Evodiamine Derivatives as Highly Selective PDE5 Inhibitors Targeting a Unique Allosteric Pocket.
Zhang T; Lai Z; Yuan S; Huang YY; Dong G; Sheng C; Ke H; Luo HB
J Med Chem; 2020 Sep; 63(17):9828-9837. PubMed ID: 32794708
[TBL] [Abstract][Full Text] [Related]
23. Multifunctional Isosteric Pyridine Analogs-Based 2-Aminothiazole: Design, Synthesis, and Potential Phosphodiesterase-5 Inhibitory Activity.
Hussein AHM; Khames AA; El-Adasy AA; Atalla AA; Abdel-Rady M; Hassan MIA; Abou-Salim MA; Elshaier YAMM; Barakat A
Molecules; 2021 Feb; 26(4):. PubMed ID: 33572094
[TBL] [Abstract][Full Text] [Related]
24. Selectivity of avanafil, a PDE5 inhibitor for the treatment of erectile dysfunction: implications for clinical safety and improved tolerability.
Wang R; Burnett AL; Heller WH; Omori K; Kotera J; Kikkawa K; Yee S; Day WW; DiDonato K; Peterson CA
J Sex Med; 2012 Aug; 9(8):2122-9. PubMed ID: 22759639
[TBL] [Abstract][Full Text] [Related]
25. In silico design of novel hERG-neutral sildenafil-like PDE5 inhibitors.
Kayık G; Tüzün NŞ; Durdagi S
J Biomol Struct Dyn; 2017 Oct; 35(13):2830-2852. PubMed ID: 27581752
[TBL] [Abstract][Full Text] [Related]
26. Design, synthesis and biological evaluation of pyrazolopyrimidinone based potent and selective PDE5 inhibitors for treatment of erectile dysfunction.
Reddy GL; Dar MI; Hudwekar AD; Mahajan P; Nargotra A; Baba AM; Nandi U; Wazir P; Singh G; Vishwakarma RA; Syed SH; Sawant SD
Bioorg Chem; 2019 Aug; 89():103022. PubMed ID: 31181491
[TBL] [Abstract][Full Text] [Related]
27. [Current role of sildenafil in the management of erectile dysfunction].
Akhvlediani ND; Matyukhov IP
Urologiia; 2018 May; (2):142-146. PubMed ID: 29901310
[TBL] [Abstract][Full Text] [Related]
28. Phosphodiesterase 5 Associates With β2 Adrenergic Receptor to Modulate Cardiac Function in Type 2 Diabetic Hearts.
West TM; Wang Q; Deng B; Zhang Y; Barbagallo F; Reddy GR; Chen D; Phan KS; Xu B; Isidori A; Xiang YK
J Am Heart Assoc; 2019 Aug; 8(15):e012273. PubMed ID: 31311394
[TBL] [Abstract][Full Text] [Related]
29. Over-expression of PDE5 in Oral Squamous Cell Carcinoma - Effect of Sildenafil Citrate.
Iwasaki T; Onda T; Honda H; Hayashi K; Shibahara T; Nomura T; Takano M
Anticancer Res; 2021 May; 41(5):2297-2306. PubMed ID: 33952455
[TBL] [Abstract][Full Text] [Related]
30. Influencing Factors for Erectile Dysfunction of Young Adults with No Response to PDE5i.
Wang J; Wang YL; He Y; Li S; Zhang YP; Cheng YB; Guo JL; Sun L; Xin Y; Tang Y; Zhu ZH; Zeng HQ
Curr Med Sci; 2021 Jun; 41(3):529-534. PubMed ID: 34169423
[TBL] [Abstract][Full Text] [Related]
31. Identification of Potential Inhibitors of PDE5 based on Structure-based Virtual Screening Approaches.
Xu L; Sun L; Su P; Ma T; Yu Y; Liu H; Huang X
Curr Comput Aided Drug Des; 2023; 19(3):234-242. PubMed ID: 36503473
[TBL] [Abstract][Full Text] [Related]
32. PDE5 inhibitors - pharmacology and clinical applications 20 years after sildenafil discovery.
Andersson KE
Br J Pharmacol; 2018 Jul; 175(13):2554-2565. PubMed ID: 29667180
[TBL] [Abstract][Full Text] [Related]
33. From Celecoxib to a Novel Class of Phosphodiesterase 5 Inhibitors: Trisubstituted Pyrazolines as Novel Phosphodiesterase 5 Inhibitors with Extremely High Potency and Phosphodiesterase Isozyme Selectivity.
Abdel-Halim M; Sigler S; Racheed NAS; Hefnawy A; Fathalla RK; Hammam MA; Maher A; Maxuitenko Y; Keeton AB; Hartmann RW; Engel M; Piazza GA; Abadi AH
J Med Chem; 2021 Apr; 64(8):4462-4477. PubMed ID: 33793216
[TBL] [Abstract][Full Text] [Related]
34. Avanafil, a new rapid-onset phosphodiesterase 5 inhibitor for the treatment of erectile dysfunction.
Limin M; Johnsen N; Hellstrom WJ
Expert Opin Investig Drugs; 2010 Nov; 19(11):1427-37. PubMed ID: 20939743
[TBL] [Abstract][Full Text] [Related]
35. The discovery of UK-369003, a novel PDE5 inhibitor with the potential for oral bioavailability and dose-proportional pharmacokinetics.
Rawson DJ; Ballard S; Barber C; Barker L; Beaumont K; Bunnage M; Cole S; Corless M; Denton S; Ellis D; Floc'h M; Foster L; Gosset J; Holmwood F; Lane C; Leahy D; Mathias J; Maw G; Million W; Poinsard C; Price J; Russel R; Street S; Watson L
Bioorg Med Chem; 2012 Jan; 20(1):498-509. PubMed ID: 22100260
[TBL] [Abstract][Full Text] [Related]
36. Medicinal plants as a potential source of Phosphodiesterase-5 inhibitors: A review.
Anand Ganapathy A; Hari Priya VM; Kumaran A
J Ethnopharmacol; 2021 Mar; 267():113536. PubMed ID: 33137431
[TBL] [Abstract][Full Text] [Related]
37. Resveratrol and sildenafil synergistically improve diabetes-associated erectile dysfunction in streptozotocin-induced diabetic rats.
Bai Y; An R
Life Sci; 2015 Aug; 135():43-8. PubMed ID: 26006044
[TBL] [Abstract][Full Text] [Related]
38. Identifying Phosphodiesterase-5 Inhibitors with Drug Repurposing Approach: Implications in Vasodysfunctional Disorders.
Khan MS; Mohammad HA; Shahwan M; Yadav DK; Anwar S; Shamsi A
ChemistryOpen; 2024 May; 13(5):e202300196. PubMed ID: 38060834
[TBL] [Abstract][Full Text] [Related]
39. Structure -activity relationships of PDE5 inhibitors.
Eros D; Szántai-Kis C; Kiss R; Kéri G; Hegymegi-Barakonyi B; Kövesdi I; Orfi L
Curr Med Chem; 2008; 15(16):1570-85. PubMed ID: 18673225
[TBL] [Abstract][Full Text] [Related]
40. Exploring the association between erectile rigidity and treatment adherence with sildenafil.
Mazzola CR; Deveci S; Teloken P; Mulhall JP
J Sex Med; 2013 Jul; 10(7):1861-6. PubMed ID: 23253943
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
